Johnson & Johnson has introduced a new type of diabetes medication amid controversy snowballed by hundreds of Januvia and Byetta lawsuit filings, and it may just change the game for diabetics.

According to an April 21st report from the MotleyFool.com, the new drug is called Invokana, and is the first of its class to be approved by the U.S. Food and Drug Administration (FDA). Johnson & Johnson has not released stand-alone sales of the drug since its entrance into the market, but has reported 15 percent growth in sales, equating to $300 million, related to a number of medications. According to the MotleyFool, Invokana is a SGLT2 inhibitor, and works by targeting protein in the kidney that aids in glucose reabsorption. By blocking the kidney’s ability to absorb glucose, more can be eliminated through the patient’s urine and levels are allowed to fall.

Byetta Lawsuit Litigation Continues to Increase as Drug Market Grows

Invokana was introduced to the U.S. market as the diabetes drug market began to soar, and the litigation involving another type of medications, continued to take shape. Drugs part of this class are referred to as incretin mimetics, and include Byetta, Victoza and Januvia, to name a few. These drugs work by mimicking the actions of incretin, a hormone that stimulates the release of insulin. According to data from ExpressScripts, not only did Americans spend 14% more on diabetes drugs in 2013 than they did a year earlier, it is also estimated that 70 million people in North America, Europe and other developing regions have been diagnosed with the disease.

Over the past few years, the use of incretin mimetics have been tied to pancreatitis, pancreatic cancer and even thyroid cancer in a growing number of product liability lawsuits. Plaintiffs involved in Byetta lawsuit filings, as well as claims over Januvia, Victoza and other drugs similarly accuse their manufacturers of failing to adequately warn about dangers associated with their products. They further allege that the Type 2 diabetes medications were designed defectively.

According to court documents, the number of Byetta pancreatic cancer claims, as well as suits over similarly-designed medications is on the rise in a federal multidistrict litigation (MDL) established in the U.S. District Court, Southern District of California. A Case List updated on April 15th indicates that 354 cases have now been consolidated in this proceeding.

A month earlier, a court update from the U.S. Judicial Panel on Multidistrict Litigation showed 320 claims filed in the California court.

How to File a Byetta Lawsuit

If you took Byetta, Januvia or another incretin mimetic, the time is now to call an attorney who can help you file a claim. Contact our Firm directly at (877) 779-1414.

Published April 22, 2014 by